Record levels of VC financing and R&D boom left biopharma companies clamoring for space. How bad is it?

There are multiple ways to measure just how vibrant the life science industry is: the influx of venture capital (now retreating slightly from a record high), the number of new incubators and startups and Big Pharma spinoffs (still going strong despite slowing down), the M&A as well as partnership deals (megabillions in cash were exchanged just last year), and so on. But one metric is particularly helpful if you want to track activities on the ground, and that is real estate occupancy.